Cancer treatment communications最新文献

{"title":"Predictors of recurrence and patterns of failure among patients treated with nephroureterectomy for upper tract urothelial carcinoma","authors":"Ryan T. Hughes ,&nbsp;John T. Lucas ,&nbsp;Louis Spencer Krane ,&nbsp;Jude L. Divers ,&nbsp;Ashok K. Hemal ,&nbsp;Bart A. Frizzell","doi":"10.1016/j.ctrc.2015.12.004","DOIUrl":"10.1016/j.ctrc.2015.12.004","url":null,"abstract":"<div><h3>Purpose</h3><p>Recurrence rates following nephroureterectomy (NU) for upper tract urothelial carcinoma (UTUC) remain high. As such, adjuvant therapy directed at high risk sites may improve long term outcomes. We describe patterns and predictors of UTUC recurrence according to patient, disease and treatment-related factors.</p></div><div><h3>Methods and materials</h3><p>We reviewed the records of 113 patients treated with NU for UTUC at our institution between 2006 and 2013. Time to locoregional (LR), intravesical (IV), distant recurrence and death were described using the Kaplan–Meier method and compared using the log rank statistic. Cox Proportional Hazards analyses were performed to evaluate the adjusted hazard for LR/IV and LR recurrence.</p></div><div><h3>Results</h3><p>Advanced T stage (T3/4) was present in 41 (36%) patients, 10 (9%) were node-positive and 21 (19%) showed evidence of lymphovascular space invasion (LVSI). Median overall survival and time to any recurrence was 54.6 and 20.7 months, respectively. Disease recurrence was observed in 48 (42%) patients. The location of failure was intravesical in 27 (24%), locoregional in 22 (19%) and distant in 20 (18%). Three-year LR/IV and distant failure rates were 38.7% and 22.2%, respectively. Three-year LR failure was 4.6% in pTa-2 vs. 25.8% in T3–T4 disease. Multivariate analysis identified history of prior bladder disease as a significant predictor of LR/IV recurrence.</p></div><div><h3>Conclusions</h3><p>In this study we demonstrate LR/IV recurrence as the predominant pattern of failure in UTUC patients treated with nephroureterectomy. This systematic description of recurrence patterns and associated factors will guide further investigation of adjuvant therapy to minimize the treatment failures defined herein.</p></div>","PeriodicalId":90461,"journal":{"name":"Cancer treatment communications","volume":"5 ","pages":"Pages 39-45"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ctrc.2015.12.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54050890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of chemotherapy strategy using bevacizumab for non-squamous non-small cell lung cancer in a real-world setting: A multi-institutional observational study","authors":"Masayoshi Higashiguchi ,&nbsp;Takashi Kijima ,&nbsp;Osamu Morimura ,&nbsp;Akio Osa ,&nbsp;Hidekazu Suzuki ,&nbsp;Takako Inoue ,&nbsp;Hiroyuki Kagawa ,&nbsp;Kiyonobu Ueno ,&nbsp;Tomonori Hirashima ,&nbsp;Toru Kumagai ,&nbsp;Fumio Imamura ,&nbsp;Masahide Mori ,&nbsp;Yoshiro Tanio ,&nbsp;Ichiro Kawase","doi":"10.1016/j.ctrc.2015.11.004","DOIUrl":"10.1016/j.ctrc.2015.11.004","url":null,"abstract":"<div><h3>Micro-abstract</h3><p>We retrospectively analyzed 162 patients with non-squamous non-small cell lung cancer (NSCLC) who underwent first-line chemotherapy with bevacizumab (BEV); 127 patients without driver oncogenes, 17 patients with <em>EGFR</em> major mutations, 12 patients with <em>ALK</em> rearrangements, 4 patients with <em>EGFR</em> minor mutations and 2 patients with rare types of histology.</p></div><div><h3>Background</h3><p>BEV has been approved for treatment of non-squamous NSCLC and is authenticated as one of the key drugs in the treatment of advanced non-squamous NSCLC.</p></div><div><h3>Patients and methods</h3><p>We retrospectively analyzed patients with stage IIIB/IV non-squamous NSCLC who underwent chemotherapy with BEV in first-line setting.</p></div><div><h3>Results</h3><p>In 162 patients who underwent chemotherapy combined with BEV as first-line treatment, the median overall survival (OS) and progression-free survival (PFS) were 23.5 months and 6.8 months, respectively. The PFS did not differ significantly by the presence of driver oncogenes. In patients without driver oncogenes, more patients who received carboplatin plus pemetrexed with BEV could complete at least 4 cycles of induction therapy and more of these patients proceeded to maintenance therapy than those who received carboplatin plus paclitaxel with BEV, which resulted in better outcome associated with carboplatin plus pemetrexed with BEV. Continuation of BEV beyond first progression did not show any survival benefit. In <em>EGFR</em> mutation-positive patients, the order of BEV-containing regimen and TKI did not influence on OS. None of 18 patients with brain metastases detected at diagnosis developed intracranial hemorrhage.</p></div><div><h3>Conclusions</h3><p>PFS of first-line chemotherapy using BEV was not influenced by the existence of driver oncogenes. In patients without driver mutations in real clinical practice, as the first-line partner regimen with BEV, carboplatin plus pemetrexed may be more feasible as compared to carboplatin plus paclitaxel. BEV use beyond first progression did not deliver significant survival benefit. BEV was safe for brain metastases.</p></div>","PeriodicalId":90461,"journal":{"name":"Cancer treatment communications","volume":"5 ","pages":"Pages 1-10"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ctrc.2015.11.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54050581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trastuzumab emtansine associated nodular regenerative hyperplasia: A case report and review of literature","authors":"L.H. Prochaska,&nbsp;I. Damjanov,&nbsp;R.M. Ash,&nbsp;J.C. Olson,&nbsp;Q.J. Khan,&nbsp;P. Sharma","doi":"10.1016/j.ctrc.2015.11.008","DOIUrl":"10.1016/j.ctrc.2015.11.008","url":null,"abstract":"<div><h3>Background</h3><p>Trastuzumab emtansine (T-DM1), a novel drug-antibody conjugate, has shown promising activity in HER2-positive breast cancer and is the recommended agent of choice for second line therapy for advanced HER 2-positive breast cancer. Elevations in transaminase levels have been reported in up to 40% of patients treated with T-DM1 on phase I-III clinical studies. More serious hepatotoxicity can also result from this drug-antibody conjugate, but has been infrequently described in the literature.</p></div><div><h3>Case Presentation</h3><p>Here we report a 73 year old female with previously untreated metastatic HER 2-positive breast cancer who developed nodular regenerative hyperplasia and noncirrhotic portal hypertension while on treatment with single agent T-DM1. Liver biopsy demonstrated nodular regenerative hyperplasia, bile duct injury, and portal fibrosis.</p></div><div><h3>Conclusion</h3><p>A high index of suspicion for liver injury and NRH must be maintained for patients who develop liver test abnormalities and/or signs of portal hypertension during treatment with T-DM1. Abdominal imaging, liver biopsy, and prompt discontinuation of T-DM1 is recommended for patients with signs or symptoms of liver injury.</p></div>","PeriodicalId":90461,"journal":{"name":"Cancer treatment communications","volume":"5 ","pages":"Pages 26-30"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ctrc.2015.11.008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54050657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“Granulocytic sarcoma of cervical lymphnode: A diagnostic challenge”","authors":"Hemlata Das ,&nbsp;Jagadish Hansa ,&nbsp;Mahesh Chandra Sahu ,&nbsp;Rabindra Nath Padhy","doi":"10.1016/j.ctrc.2016.02.005","DOIUrl":"10.1016/j.ctrc.2016.02.005","url":null,"abstract":"<div><h3>Introduction</h3><p>Granulocytic sarcoma is an event associated with acute or chronic myeloid leukemia in which, the extramedullary site consists of myeloid blasts and/or immature myeloid cells. Primary granulocytic sarcoma becomes a diagnostic challenge especially in the absence of cited hematological disorder or when lymphnode becomes an extramedullary with remote co-incidence.</p></div><div><h3>Presentation of case</h3><p>This is a case of granulocytic sarcoma in a 15-year-old girl, who presented with a mass in the right side of neck, along with progressive dysphagia and aphasia. Histomorphologic diagnosis of the tissue was supported by immunohistochemical study with Avidin-biotin-peroxidase complex technique that was performed on formalin fixed tissue from the patient.</p></div><div><h3>Discussion</h3><p>The clinicopathologic diagnosis remains an elusive decision with a malignant lymphoma, because of the isolated cervical mass presentation. Moreover, the patient was hemodynamically stable without the presence of any leukemic blast cell in the peripheral blood.</p></div><div><h3>Conclusion</h3><p>Immunohistochemical study of the tissue from the neck mass helped to reach a correct diagnosis. The diagnosis was further reconfirmed on bone marrow trephine biopsy. A final trial with myeloid panel markers was the last alternatives to all differential diagnosis to round cell tumor. Tumor cells were immunoreactive to CD68, CD34, CD117 and myeloperoxidase, suggesting myeloid sarcoma.</p></div>","PeriodicalId":90461,"journal":{"name":"Cancer treatment communications","volume":"7 ","pages":"Pages 17-20"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ctrc.2016.02.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54051252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"WITHDRAWN: Rapid and dramatic response to alectinib in an ALK rearranged NSCLC patient with poor performance status and disseminated intravascular coagulation","authors":"T. Yoshida, T. Hida, Y. Yatabe","doi":"10.1016/J.CTRC.2015.09.008","DOIUrl":"https://doi.org/10.1016/J.CTRC.2015.09.008","url":null,"abstract":"","PeriodicalId":90461,"journal":{"name":"Cancer treatment communications","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2015-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/J.CTRC.2015.09.008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54050455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in the diagnosis and treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma","authors":"Martin Hutchings ,&nbsp;Miguel A. Piris ,&nbsp;Otavio Baiocchi ,&nbsp;Mark Hertzberg","doi":"10.1016/j.ctrc.2015.06.002","DOIUrl":"10.1016/j.ctrc.2015.06.002","url":null,"abstract":"<div><p>Current management of Hodgkin lymphoma (HL) allows high cure rates to be achieved with initial therapy in both early-stage and advanced-stage disease. However, adverse events and the emergence of late effects are important issues for patients who respond well to frontline treatment. A further challenge in HL is the treatment of patients who are either refractory to, or relapse following, initial therapy. High-dose chemotherapy with autologous stem cell transplantation (HDCT/ASCT) is a potentially curative second-line treatment option for many patients with relapsed/refractory (R/R) HL. However, not all patients are candidates for HDCT/ASCT, and the frequency and duration of responses vary. For patients who fail HDCT/ASCT, current treatment options include further salvage chemotherapy, allogeneic transplantation or novel targeted therapies. Similar issues surround the management of R/R systemic anaplastic large cell lymphoma (sALCL), which is a rare and aggressive tumour. CD30 is strongly expressed in both HL and sALCL tumour cells and is a promising therapeutic target, as demonstrated by the activity of the novel antibody–drug conjugate brentuximab vedotin. New approaches to individualising and optimising patient management, including improved application of imaging, better prognostication through use of biomarkers and the potential use of new treatment combinations and agents targeting signalling pathways in malignant cells, may help to improve outcomes. The case studies included herein were presented at a symposium during the European Hematology Association (EHA) meeting in 2014. This publication aims to share clinical experiences and solutions to the management of HL and sALCL patients in very challenging disease settings.</p></div>","PeriodicalId":90461,"journal":{"name":"Cancer treatment communications","volume":"4 ","pages":"Pages S1-S11"},"PeriodicalIF":0.0,"publicationDate":"2015-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ctrc.2015.06.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54050184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"WITHDRAWN: Relationship between breast density and selective estrogen-receptor modulators, aromatase inhibitors, physical activity, and diet-a diet – A systematic review","authors":"E. Ekpo, P. Brennan, C. Mello-Thoms, M. McEntee","doi":"10.1016/J.CTRC.2015.07.002","DOIUrl":"https://doi.org/10.1016/J.CTRC.2015.07.002","url":null,"abstract":"","PeriodicalId":90461,"journal":{"name":"Cancer treatment communications","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2015-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/J.CTRC.2015.07.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54050241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Giant solitary neurofibroma in the breast: A case report and review of the literature","authors":"Chao Shao ,&nbsp;Jingjing Zhang ,&nbsp;Feihai Ling ,&nbsp;Jianhua Fu ,&nbsp;Zhihua Huang","doi":"10.1016/j.ctrc.2015.03.004","DOIUrl":"10.1016/j.ctrc.2015.03.004","url":null,"abstract":"<div><p>Solitary neurofibromas are a benign tumor composed of a mixture of Schwann, perineurial-like, and fibroblastic cells. Neurofibroma of the breast is rare. In this article, we reported a case of a giant solitary neurofibroma of the breast in a 48-year-old Chinese female. To our knowledge, this is the first case of breast giant solitary neurofibroma originating from the upper margin of the breast near the neck.</p></div>","PeriodicalId":90461,"journal":{"name":"Cancer treatment communications","volume":"4 ","pages":"Pages 19-22"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ctrc.2015.03.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54050005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epithelioid hemangioendothelioma treated with bevacizumab: A case series","authors":"Emmanouil Merikas,&nbsp;Dimitra Grapsa,&nbsp;Evangelia Dikoudi,&nbsp;Ioannis Gkiozos,&nbsp;Paraskevi Boura,&nbsp;Andriani Charpidou,&nbsp;Elias Kainis,&nbsp;Konstantinos Syrigos","doi":"10.1016/j.ctrc.2015.05.005","DOIUrl":"10.1016/j.ctrc.2015.05.005","url":null,"abstract":"<div><h3>Introduction</h3><p>Epithelioid hemangioenthothelioma (EH) is a rare vascular neoplasm of endothelial origin. It most commonly develops in the lung and liver, but may also arise from any organ, and typically displays an intermediate clinical behavior between haemangioma and angiosarcoma. Because of the rarity of this tumor no standard therapy has been proposed. Targeted antiangiogenic therapy using bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been previously reported in very few isolated cases with contradictive results.</p></div><div><h3>Presentation of cases</h3><p>We herein report a case series of four patients with EH, including two cases of localized lung and pleural EH and two cases of liver and bone EH with pulmonary metastases, which were all treated with bevacizumab.</p></div><div><h3>Discussion</h3><p>Among our studied cases, bevacizumab monotherapy was well tolerated and resulted in stable disease in three patients with advanced-stage lung, liver and bone EH, for a period of 11, 7 and 12 months, respectively. Moreover, in one of these cases (primary liver EH with pulmonary metastases), long-term disease stabilization for an additional period of 17 months was observed following administration of chemotherapy with cyclophosphamide, adriamycin and vincristine (CAV) and hepatic arterial chemoembolization combined with thalidomide.</p></div><div><h3>Conclusion</h3><p>Bevacizumab monotherapy at 15<!--> <!-->mg/kg may benefit the outcome of patients with advanced EH. We also report a long-term disease stabilization following treatment with CAV and hepatic arterial chemoembolization combined with thalidomide, in a case of liver EH with pulmonary metastases.</p></div>","PeriodicalId":90461,"journal":{"name":"Cancer treatment communications","volume":"4 ","pages":"Pages 59-64"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ctrc.2015.05.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54050154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First report of a Japanese phase I study of triplet plus bevacizumab for chemotherapy-naive metastatic colorectal cancer (J1-TRIBE study)","authors":"Hironaga Satake,&nbsp;Akihito Tsuji,&nbsp;Takeshi Kotake,&nbsp;Yoshihiro Okita,&nbsp;Yukimasa Hatachi","doi":"10.1016/j.ctrc.2015.05.003","DOIUrl":"10.1016/j.ctrc.2015.05.003","url":null,"abstract":"<div><h3>Background</h3><p>The aim of this study was to determine the recommended dose of irinotecan (CPT-11) with fixed regimen of oxaliplatin (L-OHP)/fluorouracil (5-FU)/leucovorin (LV) (FOLFOXIRI) plus bevacizumab in Japanese patients with metastatic colorectal cancer.</p></div><div><h3>Patients and methods</h3><p>Patients received CPT-11 followed by L-OHP 85<!--> <!-->mg/m², LV 200<!--> <!-->mg/m², and 5-FU 3200<!--> <!-->mg/m² infused as a 48-h continuous infusion and bevacizumab 5<!--> <!-->mg/kg, repeated every 2 weeks. A decrease of the CPT-11 dose was planned (started at level 1: CPT-11 165<!--> <!-->mg/m²). This trial was registered with the University Hospital Medical Information Network (number UMIN000012991).</p></div><div><h3>Results</h3><p>Six patients were enrolled, and MTD was not reached at level 1. CPT-11 165<!--> <!-->mg/ in combination with L-OHP 85<!--> <!-->mg/m², LV 200<!--> <!-->mg/m², 5-FU 3200<!--> <!-->mg/m² infused as a 48-h continuous infusion and bevacizumab 5<!--> <!-->mg/kg could be administered with acceptable toxicity, and all patients were treated at these dose levels. The most common grade 3 or 4 toxicities were neutropenia (67%) and leukopenia (50%). No treatment death was observed. The overall response rate was 67% (95% confidence interval: 30.0–90.3 %).</p></div><div><h3>Conclusion</h3><p>This biweekly triplet plus bevacizumab regimen was well tolerated by Japanese patients with metastatic colorectal cancer. The recommended phase II dose was determined to be the same as the standard doses for this regimen used worldwide.</p></div><div><h3>Micro abstract</h3><p>The efficacy of the FOLFOXIRI plus bevacizumab regimen for patients with metastatic colorectal cancer has been proven in a recent phase III study. However, there is no report of the FOLFOXIRI plus bevacizumab regimen in Japanese patients, and recommended doses of this regimen for Japanese patients have not been determined. The present study demonstrates that the recommended doses of FOLFOXIRI plus bevacizumab for Japanese patients are the same as the standard doses used worldwide.</p></div>","PeriodicalId":90461,"journal":{"name":"Cancer treatment communications","volume":"4 ","pages":"Pages 75-80"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ctrc.2015.05.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54050113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}